Biotherapy Services are very pleased to announce our RAPID-1 (Diabetic Foot Ulcer) trial has enrolled and dosed its first patient following suspension of the trial due to the Covid-19 pandemic restrictions. This could only have been made possible with the collaborative approach from the PHARMExcel team, who took over the trial management in early 2020….
Investors in People Silver accreditation acknowledges that PHARMExcel has been awarded one of the highest levels of accreditation within the Investors in People framework. The Silver accreditation is usually awarded to the top 5% of organisations assessed.
PHARMExcel are delighted to have be selected as INmuneBio’s U.K. CRO to lead on their Phase I clinical trial of INKmune, a novel therapy to prime the patient’s own Natural Killer (NK) cells to attack their cancer, in patients with high-risk Myelodysplastic Syndrome (MDS) (EUDRACT 2019-004820-40). This is a single center, Phase I trial and will…
BACKGROUND PHARMExcel was selected to manage a UK, Phase II, combined Investigational Medicinal Product (IMP)/Medical Device study for COVID-19 patients hospitalised in ICU. We were asked to provide Project Management (PM), Monitoring and Safety oversight for the study, from protocol development to close-out. The study involved two sites and numerous teams responsible for key elements…
PHARMExcel are delighted to be involved in delivering a Covid 19 study in collaboration with Southampton University. We are facilitating fast track approvals and delivery, aiming for site activation by the end of May
